Lung Cancer Survival with Current Therapies and New Targeted Treatments: A Comprehensive Update from the Srinagarind Hospital-Based Cancer Registry from (2013 to 2017)
- PMID: 34452564
- PMCID: PMC8629471
- DOI: 10.31557/APJCP.2021.22.8.2501
Lung Cancer Survival with Current Therapies and New Targeted Treatments: A Comprehensive Update from the Srinagarind Hospital-Based Cancer Registry from (2013 to 2017)
Abstract
Background: Lung cancer (LC) is a common malignancy and leading cause of cancer death worldwide and in Thailand. An update on LC survival factors after diagnosis at Srinagarind Hospital is needed.
Methods: We conducted a retrospective cohort study, and the data were sourced from the Srinagarind Hospital-Based Cancer Registry. All LC cases were diagnosed between January 1, 2013, and December 31, 2017, and followed up until November 30, 2019. Cases of LC (ICD-O-3) numbered 2,149, but only those with coding C34.0-C34.9 were included. The survival rate was estimated using Kaplan-Meier, while the Log-rank test was used to estimate survival. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazard regression models.
Results: The 2,149 patients had a total follow-up of 269.6 person-years. Overall, 1,867 patients died during the study, for a corresponding case-fatality mortality rate of 86.0 per 100 person-years. The respective 1-, 3-, and 5-year survival rate was 31.2 % (95% CI; 29.21 to 33.15%), 12.9 % (95%CI: 11.49 to 14.45), and 10.2% (95%CI: 8.74 to 11.70). After patient diagnosis, the median survival time was 0.46 years (5.51 months) (95% CI: 0.42 to 0.50). Targeted therapy was associated with longer survival than non-targeted therapy (p-value < 0.001). After adjusting for sex, TNM stage, and histologic type, multivariable analysis of the entire cohort identified chemotherapy as an independent predictor of improved survival (adjusted HR= 0.48; 95% CI: 0.42 to 0.55; P < 0.001), and that sex, TNM stage, and histologic type were associated with survival.
Conclusion: The study confirmed that sex, stage of disease, histology, and chemotherapy are associated with survival of LC. Primary prevention and screening for early detection improve survival. Further investigations into factors affecting survival of LC in Northeast Thailand should focus on targeted therapy.<br />.
Keywords: Lung cancer; cancer registry; survival; targeted therapy.
Figures
Similar articles
-
Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy.Int J Cancer. 2015 Mar 1;136(5):E387-95. doi: 10.1002/ijc.29216. Epub 2014 Sep 30. Int J Cancer. 2015. PMID: 25219898
-
Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis.BMC Cancer. 2020 Apr 5;20(1):276. doi: 10.1186/s12885-020-06734-3. BMC Cancer. 2020. PMID: 32248816 Free PMC article.
-
Favorable trends in lung cancer incidence with unfavorable survival prognosis: A spatiotemporal analysis by histology in Córdoba, Argentina.Cancer Epidemiol. 2025 Jun;96:102796. doi: 10.1016/j.canep.2025.102796. Epub 2025 Mar 13. Cancer Epidemiol. 2025. PMID: 40081021
-
Survival of Cancer Patients with Co-Morbid Tuberculosis in Thailand.Asian Pac J Cancer Prev. 2021 Aug 1;22(8):2701-2708. doi: 10.31557/APJCP.2021.22.8.2701. Asian Pac J Cancer Prev. 2021. PMID: 34452577 Free PMC article.
-
20-Year Comparative Survival and Mortality of Cancer of the Stomach by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration & Selected ICD-O-3 Oncologic Phenotypes: A Systematic Review of 157,258 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).J Insur Med. 2019;48(1):5-23. doi: 10.17849/insm-48-1-1-19.1. Epub 2019 Oct 14. J Insur Med. 2019. PMID: 31609640
Cited by
-
Cuproptosis: a novel therapeutic mechanism in lung cancer.Cancer Cell Int. 2025 Jun 24;25(1):231. doi: 10.1186/s12935-025-03864-1. Cancer Cell Int. 2025. PMID: 40555995 Free PMC article. Review.
-
Expert recommendations for biomarker evaluation of advanced non-small cell lung cancer in Thailand.Transl Lung Cancer Res. 2025 Jul 31;14(7):2387-2402. doi: 10.21037/tlcr-2025-201. Epub 2025 Jul 28. Transl Lung Cancer Res. 2025. PMID: 40799428 Free PMC article. Review.
-
Survival Analysis of Lung Cancer: A 10-Year Real-Life Experience in a Non-University-Based Hospital in Thailand (2012-2021).Asian Pac J Cancer Prev. 2023 Sep 1;24(9):3021-3027. doi: 10.31557/APJCP.2023.24.9.3021. Asian Pac J Cancer Prev. 2023. PMID: 37774053 Free PMC article.
-
Characteristics and patient-reported outcomes of long-term lung cancer survivors.J Thorac Dis. 2024 Feb 29;16(2):1087-1096. doi: 10.21037/jtd-23-1494. Epub 2024 Feb 22. J Thorac Dis. 2024. PMID: 38505031 Free PMC article.
-
Positive Association of Serum Vitamin B6 Levels with Intrapulmonary Lymph Node and/or Localized Pleural Metastases in Non-Small Cell Lung Cancer: A Retrospective Study.Nutrients. 2023 May 17;15(10):2340. doi: 10.3390/nu15102340. Nutrients. 2023. PMID: 37242223 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
-
- Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122:1037–57. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical